Allergan PLC (NYSE:AGN)’s share price dropped 2.6% during mid-day trading on Monday . The stock traded as low as $242.24 and last traded at $247.23, with a volume of 4,438,284 shares trading hands. The stock had previously closed at $253.85.

AGN has been the topic of several research reports. S&P Equity Research reissued a “buy” rating on shares of Allergan PLC in a report on Tuesday, April 12th. Piper Jaffray Cos. lowered shares of Allergan PLC from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $311.00 to $238.00 in a report on Monday, April 18th. Guggenheim initiated coverage on shares of Allergan PLC in a report on Monday, April 18th. They set a “neutral” rating on the stock. Goldman Sachs Group Inc. reissued a “buy” rating and set a $275.00 price objective on shares of Allergan PLC in a report on Monday, April 18th. Finally, Deutsche Bank AG reissued a “buy” rating on shares of Allergan PLC in a report on Monday, April 18th. Seven equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $309.05.

The firm has a market capitalization of $98.22 billion and a P/E ratio of 22.22. The stock’s 50 day moving average is $241.61 and its 200 day moving average is $252.08.

Allergan PLC (NYSE:AGN) last posted its earnings results on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $3.35. The business had revenue of $3.68 billion for the quarter, compared to analysts’ expectations of $4.10 billion. The business’s revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the business posted $4.41 earnings per share. Equities analysts expect that Allergan PLC will post $14.21 earnings per share for the current year.

In other news, CFO Maria Teresa Hilado purchased 661 shares of the stock in a transaction dated Thursday, June 2nd. The stock was acquired at an average cost of $241.57 per share, for a total transaction of $159,677.77. Following the completion of the acquisition, the chief financial officer now directly owns 11,957 shares in the company, valued at approximately $2,888,452.49. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Nesli Basgoz sold 459 shares of Allergan PLC stock in a transaction dated Wednesday, May 11th. The stock was sold at an average price of $225.10, for a total transaction of $103,320.90. Following the sale, the director now owns 5,242 shares of the company’s stock, valued at $1,179,974.20. The disclosure for this sale can be found here.

Several large investors recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. boosted its stake in Allergan PLC by 2.1% in the fourth quarter. Ameritas Investment Partners Inc. now owns 7,544 shares of the company’s stock valued at $2,357,000 after buying an additional 158 shares in the last quarter. Deimos Asset Management LLC bought a new stake in Allergan PLC during the fourth quarter valued at about $2,188,000. FineMark National Bank & Trust boosted its stake in Allergan PLC by 12.5% in the fourth quarter. FineMark National Bank & Trust now owns 17,387 shares of the company’s stock valued at $5,434,000 after buying an additional 1,937 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Allergan PLC by 1.2% in the fourth quarter. Principal Financial Group Inc. now owns 533,175 shares of the company’s stock valued at $166,617,000 after buying an additional 6,382 shares in the last quarter. Finally, Signature Estate & Investment Advisors LLC boosted its stake in Allergan PLC by 12.7% in the fourth quarter. Signature Estate & Investment Advisors LLC now owns 42,141 shares of the company’s stock valued at $13,169,000 after buying an additional 4,742 shares in the last quarter.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.